CAS: 39232-91-2; 3-Methoxyphenylhydrazine Hydrochloride

该化合物是一种氢氮衍生物,通常用作有机合成和制药研究的多用途中间体,其主要优点包括:在形成异环化合物(如聚醚和等)的过程中具有高度的再活动性,因此对构建复杂的分子框架很有价值.盐的盐形式可以增强稳定性和溶性,便利处理和储存.苯环上的甲基氧替代物可以影响电子特性,使合成路径有选择地发挥作用.这种化合物对于发展农用化学,染料和生物活性分子特别有用.建议由于水合苯的再活动,在受管制条件下进行适当处理.

结构式图片

上下游产品

m-Anisidine 3-methoxyphenyl bromide 3-methoxy-1-iodobenzene H-pyrazol-4-ylazo]-N-thiazol-2-yl-benzenesulfonamide4-[1-(3-methoxy-phenyl)-3,5-dimethyl-1H-pyrazol-4-ylazo]-N-thiazol-2-yl-benzenesulfonamide N-thiazol-2-yl-benzenesulfonamide4-{[1-(3-methoxy-phenyl)-3-methyl-5-oxo-1,5-dihydro-pyrazol-4-ylidene]-hydrazino}-N-thiazol-2-yl-benzenesulfonamide 6-Methoxy-3-(4-methoxyphenyl)-2-phenylindole 4-Hydroxy-3-{1-[(3-methoxy-phenyl)-hydrazono]-ethyl}-chromen-2-one

合成工艺路线路线简述

    间氨基苯甲醚置于盐酸,Sodium Nitrite,Tin(Ll) Chloride体系中,用 水 作为反应溶剂,化学反应 1.5H,反应生成 3-甲氧基苯肼盐酸
    参考文献:发现了以ftsz为目标的含1,3,4-恶二唑-2-酮的苯甲酰胺衍生物,可作为杀死多种mdr细菌菌株的高效药物.
    标题:发现了以ftsz为目标的含1,3,4-恶二唑-2-酮的苯甲酰胺衍生物,可作为杀死多种mdr细菌菌株的高效药物.
    摘要:由耐多药(mdr)病原体(例如耐甲氧西林的金黄色葡萄球菌(mrsa)和耐万古霉素的金黄色葡萄球菌(vrsa))引起的感染扩散,引起了人们对具有新作用机制的新型抗生素的需求.细菌分裂蛋白ftsz已被鉴定为可在临床上开发的新型药物靶标.作为开发靶向ftsz的抗菌剂的持续努力的一部分,我们在此描述了六种系列的新型含1,3,4-恶二唑-2-One,1,2,4-三唑-的设计,合成和生物活性.含3-One和含吡唑啉-5-One的苯甲酰胺衍生物.其中,化合物a14被发现是最有效的抗菌剂,对所有测试的革兰氏阳性菌株均优于环丙沙星,利奈唑胺和红霉素等临床药物,特别是耐甲氧西林,耐青霉素和临床分离的金黄色葡萄球菌.随后的生物学活性和对接分析研究证明,A14可以作为靶向ftsz的有效化合物.初步的sar表明了进一步优化这些新颖类似物的总体方向.综上所述,这项研究为开发新型靶向ftsz的杀菌剂提供了有希望的化学型.
    DOI:10.1016/j.Bmc.2019.06.010

    海关参考信息

    专利信息


    专利号:US-11040938-B2
    优先权日:2016-07-27
    标 题 :Continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts
    发明人:MA BING; PAN SHUAI
    权利人:SHANGHAI HYBRID—CHEM TECH; SHANGHAI HYBRID CHEM TECH
    摘要:The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

    专利号:US-4267330-A
    优先权日:1978-08-24
    标 题 :Process for the synthesis of vincadifformine and related derivatives
    发明人:KUEHNE MARTIN E
    权利人:OMNIUM CHIMIQUE SA
    摘要:This invention relates to the preparation of vincadifformine and related derivatives which are useful as starting material for the synthesis of vincamine and other related compounds possessing interesting psychopharmacologic properties. A N-benzyl-tetrahydro- gamma -carboline compound (III) is halogenated with t-butyl hypochlorite to obtain a haloindolenine compound which is directly treated with a metal dialkyl malonate such as thallium dialkyl malonate to provide a dialkyl 3-benzyl-1,2,3,4,5,6-hexahydroazepino (4,5-b) indole-5,5-dicarboxylate compound, said latter compound being hydrogenated to provide a dialkyl 1,2,3,4,5,6 hexahydroazepino (4,5-b) indole-5,5-dicarboxylate, said latter compound being condensed with a functionalized aldehyde, typically a haloaldehyde, to provide vincadifformine or a related derivative by passing through an intermediate compound being a salt of a dialkyl 3,3-(alkenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b) indolinium-(5,5)-dicarboxylate.

    专利号:US-2016222024-A1
    优先权日:2013-09-20
    标 题:S-enantiomer of tetracyclic indole derivative as pbr ligands
    发明人:TRIGG WILLIAM JOHN; JONES PAUL ALEXANDER
    权利人:GE HEALTHCARE LTD
    摘要:The present invention concerns in vivo imaging and in particular in vivo imaging of translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor). An indole-based in vivo imaging agent is provided that overcomes problems relating to known TSPO-binding radiotracers. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said precursor compound. Other aspects of the invention include a method for the synthesis of the in vivo imaging agent of the invention comprising use of the precursor compound of the invention, a kit for carrying out said method, and a cassette for carrying out an automated version of said method. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.

    专利号:US-9481685-B2
    优先权日:2008-10-02
    标 题:Imaging neuroinflammation
    发明人:WADSWORTH HARRY JOHN; SHAN BO; O'SHEA DENNIS; PASSMORE JOANNA MARIE; TRIGG WILLIAM JOHN
    权利人:WADSWORTH HARRY JOHN; SHAN BO; O'SHEA DENNIS; PASSMORE JOANNA MARIE; TRIGG WILLIAM JOHN; GE HEALTHCARE LTD
    摘要:The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.

    专利号:US-2019152896-A1
    优先权日:2016-07-27
    标题 :Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts

    专利号:CA-1142178-A
    优先权日:1978-08-24
    标 题 :Process for the synthesis of vincadifformine and relatd derivatives
    邢台奥帆医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.allfinechem.com
    企业联系电话:0319-6802888,6808888👤
    📞邢台奥帆医药科技有限公司 ⚠️参考联系方式
    联系人:王先生
    电话:0319-6802888,6808888

    传真:0319-6802678
    邮箱:sales@allfinechem.com
    通信地址: 河北省邢台市内邱县小房岗
    邮编: 054200
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河北省邢台市内邱县小房岗
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    淄博奥特精细化工厂
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.aotechem.com
    企业联系电话:0533-8177001 13964357448张总👤
    📞淄博奥特精细化工厂 ⚠️参考联系方式
    联系人:张建敏
    电话:0533-8177001 13964357448张总
    手机:13964357448
    传真:0533-7521583
    邮箱:sales@aotechem.com
    通信地址: 淄博齐鲁乙烯北路
    邮编: 255400
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:淄博齐鲁乙烯北路
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    郑州手性药物研究院有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.chiralspharm.cn
    企业联系电话:0371-55219111👤
    📞郑州手性药物研究院有限公司 ⚠️参考联系方式
    联系人:李经理
    电话:0371-55219111
    手机:13703711903
    传真:0371-55219111
    邮箱:chiraldrug01@zzcpi.org
    通信地址: 郑州市中原西路中原智谷2号楼研发中心15层
    邮编: 450121
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:郑州市中原西路中原智谷2号楼研发中心15层
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北鸿鑫瑞宇精细化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hbhxry.com
    企业联系电话:15307120296;13477033894👤
    📞湖北鸿鑫瑞宇精细化工有限公司 ⚠️参考联系方式
    联系人:陈经理
    电话:15307120296;13477033894
    手机:18164064948
    传真:027-65526669
    邮箱:2016269472@qq.com
    通信地址: 武汉市东湖高新技术开发区关东园路​
    邮编: 430000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:武汉市东湖高新技术开发区关东园路​
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1007/s10854-021-07629-0
    摘要:Alam MM, Asiri AM, Uddin J, Rahman MM. Selective 1,4-dioxane chemical sensor development with doped ZnO/GO nanocomposites by electrochemical approach. Journal of Materials Science: Materials in Electronics. 2022 Jan 05;33(7):4360–74. doi: 10.1007/s10854-021-07629-0.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知